Overview
Study information
| Network: | CAVD |
| Grant Affiliation: | Ho: Ibalizumab for HIV Prevention |
| Strategy: | Prophylactic neutralizing Ab |
| Study Type: | Antibody Screening |
| Species: | Non-Organism Study |
| Stage: | Assays Completed |
| Study Start Date: | 2009-12-16 |
| Study Made Public: | 2010-06-22 |
Title
Assessment of ibalizumab neutralization potency and breadth
Description
CAVD 309 is an immunogenicity study to assess the potency and breadth of the monoclonal antibody, Ibalizumab, against a diverse Env-pseudotype panel.
Sign in to see full information about this study and to download study data.
Products
IbalizumabIntegrated data
NAb MAb
Non-integrated data
No non-integrated data is available for this study.